![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsors and Collaborators: |
Mayo Clinic AstraZeneca |
---|---|
Information provided by: | Mayo Clinic |
ClinicalTrials.gov Identifier: | NCT00170001 |
The investigators hypothesize that persons with the particular cluster of symptoms that are due to supraesophageal reflux (SER) will have complete resolution of those symptoms with adequate acid suppression when a PPI is administered for 6 months.
Condition | Intervention |
---|---|
Gastroesophageal Reflux |
Drug: esomeprazole magnesium |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study |
Official Title: | Which Supraesophageal Reflux Symptoms Reliably Respond to PPI Therapy: A Large Simple Trial |
Estimated Enrollment: | 500 |
Study Start Date: | April 2005 |
Estimated Study Completion Date: | March 2006 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
United States, Minnesota | |
Mayo Clinic | Recruiting |
Rochester, Minnesota, United States, 55905 | |
Contact: Melissa Westergren 507-538-1392 westergren.melissa@mayo.edu | |
Principal Investigator: Yvonne Romero, MD |
Principal Investigator: | Yvonne Romero, M.D. | Mayo Clinic |
Study ID Numbers: | 452-05, IRUSESOM0376 |
Study First Received: | September 12, 2005 |
Last Updated: | March 6, 2006 |
ClinicalTrials.gov Identifier: | NCT00170001 |
Health Authority: | United States: Food and Drug Administration |
supraesophageal reflux laryngopharyngeal symptoms pharynx esophagus |
Deglutition Disorders Esophageal Motility Disorders Digestive System Diseases Esophageal disorder |
Gastrointestinal Diseases Omeprazole Esophageal Diseases Gastroesophageal Reflux |
Molecular Mechanisms of Pharmacological Action Therapeutic Uses Anti-Ulcer Agents |
Gastrointestinal Agents Enzyme Inhibitors Pharmacologic Actions |